Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.

Aredo, Jacqueline V; Padda, Sukhmani K

Aredo, Jacqueline V; Padda, Sukhmani K.

Affiliation

Aredo JV; Department of Medicine, Division of Oncology, Stanford Cancer Institute/Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA.
Padda SK; Department of Medicine, Division of Oncology, Stanford Cancer Institute/Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA. padda@stanford.edu.

Curr Treat Options Oncol ; 19(8): 43, 2018 06 27.

Article in En | MEDLINE | ID: mdl-29951788

Subject(s)

Carcinoma, Non-Small-Cell Lung/diagnosis; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/therapy; Lung Neoplasms/diagnosis; Lung Neoplasms/genetics; Lung Neoplasms/therapy; Mutation; Precision Medicine; Proto-Oncogene Proteins p21(ras)/genetics; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung/mortality; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Lung Neoplasms/mortality; Precision Medicine/methods; Standard of Care; Treatment Outcome

Key words

Co-occurring mutation; Immunotherapy; KRAS mutation; Lung cancer; Precision medicine

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Proto-Oncogene Proteins p21(ras) / Carcinoma, Non-Small-Cell Lung / Precision Medicine / Lung Neoplasms / Mutation Type of study: Prognostic_studies Limits: Humans Language: En Journal: Curr Treat Options Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google